metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-042 (PDL1>20%), 2019 Lancet 2019;393:1819-1830 Immunotherapy 2019; 11:1463-1478 Lung Cancer 2019; 135:188-195 NCT02220894	RCT	mNSCLC - L1 - PDL1 positive	pembrolizumab	platinium based chemotherapy	previously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 20% or greater	413 / 405	some concern	conclusif	demonstrated 23 % decrease in deaths (OS) (PE) suggested 25 % decrease in deaths (OS) (extension)
	KEYNOTE-042 (PDL1>1%), 2019 Lancet 2019;393:1819-1830 Immunotherapy 2019; 11:1463-1478 Lung Cancer 2019; 135:188-195 NCT02220894	RCT	mNSCLC - L1 - PDL1 positive	pembrolizumab	platinium based chemotherapy	previously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 1% or greater	637 / 637	some concern	conclusif	demonstrated 19 % decrease in deaths (OS) (PE) suggested 20 % decrease in deaths (OS) (extension)
	KEYNOTE-042 (PDL1>50%), 2019 Lancet 2019;393:1819-1830 Immunotherapy 2019; 11:1463-1478 Lung Cancer 2019; 135:188-195 Int J Cancer 2020 Nov 24. NCT02220894	RCT	mNSCLC - L1 - PDL1 positive	pembrolizumab	platinium based chemotherapy	previously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 50% or greater	299 / 300	some concern	conclusif	demonstrated 31 % decrease in deaths (OS) (PE) suggested 2 % decrease in deaths (OS) (extension) suggested 19 % decrease in progression or deaths (PFS)
	KEYNOTE-024 (PDL1>50%), 2016 N Engl J Med 2016;375:1823-1833 Lancet Oncol. 2017; 18:1600-1609 J. Clin. Oncol. 2019; 37:537-546 Lung Cancer 2019; 135:188-195 Cancer Sci 2020 Sep 14. J Clin Oncol 2021 Apr 19;JCO2100174. NCT02142738	RCT	mNSCLC - L1 - PDL1 positive	Pembrolizumab	ICC platinum-based chemotherapies regimens	patients who had previously untreated advanced stage IV NSCLC with PD-L1 expression on at least 50% of tumor cells	154 / 151	some concern	conclusif	demonstrated 40 % decrease in deaths (OS) (PE) demonstrated 50 % decrease in progression or deaths (PFS) (PE) suggested 38 % decrease in deaths (OS) (extension) suggested 50 % decrease in PFS (extension)

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)

pembrolizumab alone